Purpose: The blinq (Rebion Inc) is a new screening device designed to directly detect amblyopia and strabismus rather than amblyopia risk factors. We performed an independent assessment of the effectiveness of the blinq in detecting amblyopia and strabismus.
Design: Prospective clinical validity analysis of a screening device based on sensitivity and specificity.
Purpose: To evaluate the Spot Vision Screener according to updated 2021 AAPOS Vision Screening Committee guidelines for instrument-based pediatric vision screen validation.
Methods: As part of an IRB-approved ongoing prospective study, children were screened with the Spot prior to a complete examination.
Results: Spot screening was successful in 1,036 of 1,090 children (95%).